Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 3—March 2006


"Mycobacterium tilburgii" Infections

Dirk Wagner*Comments to Author , Margreet C. Vos†‡, Anton G.M. Buiting‡, Annerose Serr*, Anneke M.C. Bergmans§, Winfried V. Kern*, and Leo M. Schouls¶
Author affiliations: *University Hospital, Freiburg, Germany; †Erasmus University Medical Center, Rotterdam, the Netherlands; ‡St Elisabeth Hospital, Tilburg, the Netherlands; §Franciscus Hospital, Roosendaal, the Netherlands; ¶National Institute of Public Health and the Environment, Bilthoven, the Netherlands

Main Article


Characteristics of patients with confirmed "Mycobacterium tilburgii" disease*

Sex (age, y) Immuno-suppression CD4 count (cell/μL) Disease manifestation Treatment (duration, mo) Diagnosed in Reference
F (45) No Normal Bladder, intestinal lymphnodes, stomach, ileum, colon Pyrazinamide, isoniazid, rifampin (5); ethambutol, ciprofloxacin, clarithromycin, rifampin (11); surgical resection The Netherlands This study
M (34) AIDS 37 Esophagus, duodenum Ethambutol, clarithromycin, rifabutin (5) Germany This study
M (35) AIDS 20 Duodenum, abdominal lymph nodes Ethambutol, clarithromycin, rifabutin (12†) Germany (9)
M (41) AIDS 17 Pulmonary nodules Surgical resection; ethambutol, ciprofloxacin, clarithromycin (6); ethambutol, clarithromycin (12‡) Germany (10)

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO